Episodes
Saturday Jan 06, 2024
Do Statins “REPRIEVE” People Living with HIV from CV Events?
Saturday Jan 06, 2024
Saturday Jan 06, 2024
As people living with HIV age, the risk of cardiovascular disease becomes the greatest threat to their health and quality of life. Not only does inflammation from HIV infection contribute to atherosclerotic cardiovascular disease (ASCVD), but dyslipidemia from the antivirals commonly used to treat HIV further enhances that risk. But does statin therapy reduce ASCVD risk in patients living with HIV? That's the question that the REPRIEVE study attempted to answer.
Guest Authors: Laura Lerner, PharmD and Joseph Nardolillo, PharmD, BCACP
Music by Guest Talk
Friday Nov 17, 2023
Should We Be Good SPORTs About Supplements for Cholesterol?
Friday Nov 17, 2023
Friday Nov 17, 2023
Can supplements marketed for cardiovascular health be used in place of statin therapy? Health professionals have long been wary of nutraceuticals and dietary supplements due to the lack of safety and efficacy regulations. The SPORT trial attempts to provide robust data, to practitioners and patients, on how common supplements perform compared to statin therapy.
Guest Authors: Kaitlyn Phillips, PharmD, Lindsey Pitt, PharmD, and Anna Love, PharmD, BCACP
Music by Good Talk
Tuesday Sep 05, 2023
Beyond Statins: Approaches to Lipid Lowering in 2023
Tuesday Sep 05, 2023
Tuesday Sep 05, 2023
This episode is a collaboration between the ACCP Ambulatory Care Practice and Research Network (PRN) ... and iForumRx.org.
The treatment of dyslipidemia has gotten a lot more complex in recent years as we now have several non-statins that can substantially lower LDL cholesterol and reduce cardiovascular event rates - including PCSK9 monoclonal antibodies, ezetimibe, bempedoic acid, and inclisiran. When and how should we be using these agents?
Panelists: David Dixon, PharmD, BCACP, CDCES, CLS; Kathryn Litten, PharmD, BCACP; and Tomasz Jurga, PharmD, BCPS, BCACP, BCCP, CDCES
Produced by Jonathan Hughes, PharmD, BCPS, BCACP and Anna Love, PharmD, BCACP
Music by lemonmusicstudio from Pixabay
Friday Aug 25, 2023
Fixed Dose or Treat-to-Target: Does LODESTAR Guide Us on Statin Management?
Friday Aug 25, 2023
Friday Aug 25, 2023
There has been a long-standing debate about the optimal approach to statin use, including whether we should initiate therapy using a “fixed-dose”, high-potency statin, or whether we should “start low and go slow” by titrating the dose to a specific LDL-C target. The LODESTAR study was designed to determine if treating LDL-C to a target level produces similar cardiovascular outcomes when compared to a fixed-dose approach.
Guest Authors: Dawn Fuke, PharmD, BCPS and Catherine Behret, PharmD, BCACP
Music by Good Talk
Friday Jun 09, 2023
Is There a CLEAR Role for Bempedoic Acid in Cardiovascular Risk Reduction?
Friday Jun 09, 2023
Friday Jun 09, 2023
There are a variety of non-statin lipid-lowering medications with proven cardiovascular benefits; however, most of the evidence supporting their use has been as an adjunct with a statin. Bempedoic acid offers a novel mechanism of action to treat hypercholesterolemia. But is there a CLEAR role for bempedoic acid in the treatment and prevention of ASCVD in statin-intolerant patients?
Guest Authors: Sarah B. Edwards, PharmD and Briana Williams, PharmD, BCPS, BCACP
Special Guest: Joseph Saseen, PharmD, BCPS, BCACP
Music by Good Talk
Friday Apr 14, 2023
Friday Apr 14, 2023
You’ve probably encountered many patients who have experienced muscle symptoms after starting a statin. Statin-associated muscle symptoms (SAMS) contribute to treatment discontinuation and significantly increase cardiovascular (CV) adverse events and mortality. What strategies do you recommend to increase statin tolerance?
Guest Author: Rick Hess, PharmD, CDCES, BCACP
Music by Good Talk
Friday Dec 09, 2022
Is Icosapent Ethyl a QALY-ty Investment?
Friday Dec 09, 2022
Friday Dec 09, 2022
The landmark REDUCE-IT trial demonstrated that icosapent ethyl (IPE) 4 g daily significantly reduced cardiovascular events in high-risk patients when added to statin therapy, but is a fancy fish oil supplement really worth our coin?
Guest Authors: Joseph Nardolillo, PharmD, BCACP and Vivian Cheng, PharmD, BCPS, BCACP
Music by Good Talk
Friday Jun 11, 2021
Tiny (n-of-1) Trials to Overcome Statin-Associated Muscle Pain
Friday Jun 11, 2021
Friday Jun 11, 2021
In blinded clinical trials the percentage of patients who experience muscle symptoms while taking a statin is typically in the 3-5% range. In practice, the percentage of patients who report muscle symptoms is 10-25%. This disparity between what has been observed in blinded trials and what patients experience when treated with a statin is due, in part, to the nocebo effect — a belief that a medication may cause harm. How many lives could be saved if we routinely used tiny randomized, controlled, blinded trials to determine when statin therapy can be safely continued?
Guest Panelists: Elizabeth Hearn, PharmD; Stuart T Haines PharmD, BCPS, BCACP; and Kathryn (Katie) Kiser, PharmD, BCACP
Music by Good Talk
Friday Aug 14, 2020
Will Bempedoic Acid provide SERENITY for Patients with Statin Intolerance?
Friday Aug 14, 2020
Friday Aug 14, 2020
Current guidelines recommend statins for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) due to their well-established therapeutics benefits. Unfortunately, many patients are unable to tolerate statins due to statin-associated muscle symptoms (SAMS), most commonly manifested as myalgias. Patients who are unable to tolerate a statin can be challenging to treat. Even if the patient is willing to try a lower dose or a different statin, the patient’s low-density lipoprotein cholesterol (LDL-C) may still be above the recommended threshold. This puts patients unable to tolerate statins at increased risk of ASCVD or of a recurrent cardiovascular event. Is bempedoic acid a useful therapeutic option in patients with SAMS?
Guest Authors: Kara Gurries, PharmD, BCACP and Janeen Ibarreta, PharmD
Music by Good Talk
Monday Jul 06, 2020
An Incli-ng of Benefit? Efficacy and Safety of Inclisiran for Elevated LDL
Monday Jul 06, 2020
Monday Jul 06, 2020
Lipid management continues to be an essential component in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). For the past decade, clinical practice guidelines have gone back and forth about optimal treatment goals but guidelines all agree that statins should be used as the preferred initial therapy. However, there is still a lack of clarity about the optimal add-on therapies. The newest LDL-lowering therapy is inclisiran, a small interfering RNA (siRNA) that targets the PCSK9 pathway.
Guest Authors: Joshua O. Holmes, PharmD, MS and Amanda Schartel, PharmD, BCACP
Music by Good Talk